1. Introduction
===============

Type 2 diabetes mellitus (T2DM) is one of the most common progressive metabolic diseases and poses a substantial burden on health-care systems globally. The International Diabetes Federation (IDF) has estimated that the prevalence of diabetes was 366 million worldwide, and is expected to increase up to 552 million by 2030 \[[@B1-ijms-16-00704]\]. However, the mechanisms associated with T2DM remain uncertain. It is widely accepted that T2DM is a complex disease and both environmental and genetic factors can contribute to disease initiation as well as its evolution.

Adiponectin (encoded by ADIPOQ (also known as APM1, ACRP30 or GBP28)) is an important adipocytokine that is secreted by adipocytes and plays a key role in the inflammatory response that is associated with insulin-resistant states and T2DM \[[@B2-ijms-16-00704],[@B3-ijms-16-00704],[@B4-ijms-16-00704]\]. The human *ADIPOQ* gene is mapped to chromosome 3q27 \[[@B5-ijms-16-00704]\], displays a few polymorphisms in the promoter region (e.g., −11426A\>G (rs16861194), −11391G\>A (rs17300539), −11377C\>G (rs267729)) or in the exon 2 (+45T\>G, rs16861194) or in the intron2 (+276G\>T, rs1501299), which could affect *ADIPOQ* gene transcription and its secretion \[[@B6-ijms-16-00704]\]. In recent years, the associations of single nucleotide polymorphisms (SNPs) of the *ADIPOQ* gene with T2DM have been reported \[[@B7-ijms-16-00704],[@B8-ijms-16-00704],[@B9-ijms-16-00704],[@B10-ijms-16-00704],[@B11-ijms-16-00704],[@B12-ijms-16-00704]\]. However, the results of these studies are still controversial, and show strong racial and regional variations. Therefore, we designed this meta-analysis synthesizing the data from single case-control studies to evaluate the genetic risk of the +45T\>G polymorphism in the *ADIPOQ* gene for T2DM.

2. Results
==========

2.1. Description of the Studies
-------------------------------

A total of 260 studies were identified by the literature search. Of these, the first screening excluded 187 citations based on abstracts or titles, leaving 73 articles for full text reports. Applying the study inclusion criteria, 44 studies were included in this meta-analysis ([Figure 1](#ijms-16-00704-f001){ref-type="fig"}). A total of 9786 cases and 16,022 controls were included in the +45T\>G analysis. [Table 1](#ijms-16-00704-t001){ref-type="table"} lists the main characteristics of the 44 studies eligible for the meta-analysis. These populations belong to Caucasian and Asian subgroups respectively. The Caucasian subgroup includes 14 individual studies and the Asian subgroup comprises 30 individual studies.
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###### 

Characteristics of studies included for investigation of associations between SNPs +45T\>G and type 2 diabetes risk.

  Study                      Year   Country/Ethnicity         Study Design       Genotyping Method   Cases   Controls   HWE                                                                 
  -------------------------- ------ ------------------------- ------------------ ------------------- ------- ---------- ----- ----- ------ ------ ----- ---- ----- ------ -------- -------- ------
  \[[@B6-ijms-16-00704]\]    2009   Chinese/Asian             Population-based   ARMS-PCR            480     362        74    510   1322   483    389   98   585   1355   2.23     0.62     0.14
  \[[@B12-ijms-16-00704]\]   2010   Italy/Caucasian           Cohort             RT-PCR              370     117        16    149   857    359    126   18   162   844    2.68     0.08     0.1
  \[[@B13-ijms-16-00704]\]   2002   Japanese/Asian            Population-based   PCR-DS              164     169        51    271   497    251    183   46   275   685    2.18     0.48     0.14
  \[[@B14-ijms-16-00704]\]   2003   Japanese/Asian            Population-based   PCR-DS              78      66         20    106   222    90     74    15   104   254    ＜0.01   0.31     0.97
  \[[@B15-ijms-16-00704]\]   2004   Chinese/Asian             Population-based   PCR-RFLP            104     71         20    111   279    98     74    15   104   270    0.04     0.14     0.84
  \[[@B16-ijms-16-00704]\]   2004   Chinese/Asian             Population-based   PCR-RFLP            8       46         24    94    62     39     35    11   57    113    0.49     0.04     0.48
  \[[@B17-ijms-16-00704]\]   2005   Korean/Asian              Hospital-based     SBE                 252     202        39    280   706    201    181   45   271   583    0.2      0.87     0.65
  \[[@B18-ijms-16-00704]\]   2005   Chinese/Asian             Hospital-based     PCR-RFLP            56      36         12    60    148    48     38    4    46    134    1.08     0.11     0.3
  \[[@B19-ijms-16-00704]\]   2005   Chinese/Asian             Population-based   PCR-RFLP            53      46         16    78    152    46     44    5    54    136    1.82     0.25     0.18
  \[[@B20-ijms-16-00704]\]   2006   Chinese/Asian             Population-based   PCR-RFLP            103     69         23    115   275    78     57    4    65    213    2.9      0.04     0.09
  \[[@B21-ijms-16-00704]\]   2007   Chinese/Asian             Population-based   PCR-RFLP            36      19         2     23    91     75     16    3    22    166    2.92     0.79     0.09
  \[[@B22-ijms-16-00704]\]   2007   Chinese/Asian             Hospital-based     PCR-RFLP            67      36         17    70    170    60     45    15   75    165    1.94     ＜0.01   0.16
  \[[@B23-ijms-16-00704]\]   2007   Chinese/Asian             Hospital-based     PCR-RFLP            80      92         28    148   252    122    72    6    84    316    1.44     0.85     0.23
  \[[@B24-ijms-16-00704]\]   2007   Chinese/Asian             Population-based   PCR-RFLP            39      48         13    74    126    58     40    3    46    156    1.6      0.77     0.21
  \[[@B25-ijms-16-00704]\]   2007   Chinese/Asian             Population-based   RT-PCR              20      94         54    202   134    68     60    22   104   196    2.05     0.03     0.15
  \[[@B26-ijms-16-00704]\]   2007   Chinese/Asian             Population-based   PCR-RFLP            89      79         12    103   257    152    114   20   154   418    0.05     0.32     0.83
  \[[@B27-ijms-16-00704]\]   2007   Chinese/Asian             Population-based   RT-PCR              90      36         12    60    216    48     64    20   104   160    0.03     ＜0.01   0.86
  \[[@B28-ijms-16-00704]\]   2008   Chinese/Asian             Hospital-based     PCR--RFLP           134     135        20    175   403    59     38    6    50    156    ＜0.01   0.07     0.97
  \[[@B29-ijms-16-00704]\]   2008   Chinese/Asian             Population-based   PCR-RFLP            126     115        14    143   367    76     40    4    48    192    0.21     0.06     0.65
  \[[@B30-ijms-16-00704]\]   2008   Chinese/Asian             Hospital-based     PCR-RFLP            103     75         17    109   281    79     53    6    65    211    0.61     0.53     0.43
  \[[@B31-ijms-16-00704]\]   2008   Chinese/Asian             Population-based   PCR-RFLP            55      26         16    58    136    53     41    4    49    147    1.31     ＜0.01   0.25
  \[[@B32-ijms-16-00704]\]   2008   Chinese/Asian             Population-based   PCR-RFLP            167     123        22    167   457    85     75    7    89    245    3.7      0.92     0.05
  \[[@B33-ijms-16-00704]\]   2009   Chinese/Asian             Population-based   PCR-RFLP            44      44         18    80    132    28     24    6    36    80     0.06     0.23     0.8
  \[[@B34-ijms-16-00704]\]   2009   Chinese/Asian             Population-based   PCR-RFLP            71      44         11    66    186    47     54    11   76    148    0.64     0.28     0.42
  \[[@B35-ijms-16-00704]\]   2009   Chinese/Asian             Population-based   PCR-RFLP            68      52         11    74    188    59     42    4    50    160    1.1      0.81     0.29
  \[[@B36-ijms-16-00704]\]   2010   Chinese/Asian             Hospital-based     PCR-RFLP            38      47         15    77    123    60     37    3    43    157    0.92     0.94     0.34
  \[[@B37-ijms-16-00704]\]   2011   Chinese/Asian             Population-based   PCR-RFLP            209     99         19    137   517    206    103   20   143   515    2.09     0.12     0.15
  \[[@B38-ijms-16-00704]\]   2012   Chinese/Asian             Population-based   PCR-RFLP            88      54         11    76    230    88     62    8    78    238    0.48     0.5      0.49
  \[[@B39-ijms-16-00704]\]   2012   Chinese/Asian             Population-based   PCR-RFLP            97      46         4     54    240    135    52    2    56    322    1.53     0.6      0.22
  \[[@B40-ijms-16-00704]\]   2012   Chinese/Asian             Hospital-based     PCR-SSCP            114     134        26    186   362    84     50    7    64    218    0.02     0.13     0.9
  \[[@B41-ijms-16-00704]\]   2013   Chinese/Asian             Hospital-based     PCR-DS              75      79         26    131   229    64     48    8    64    176    0.06     0.49     0.8
  \[[@B42-ijms-16-00704]\]   2002   Italy/Caucasian           Hospital-based     ARMS-PCR            242     61         7     75    545    220    75    9    93    515    0.7      0.19     0.4
  \[[@B43-ijms-16-00704]\]   2004   French/Caucasian          Population-based   RT-PCR              24      6          1     8     54     2816   847   56   959   6479   0.72     0.44     0.4
  \[[@B44-ijms-16-00704]\]   2005   Finland/Caucasian         Cohort             \-                  235     23         0     23    493    255    26    2    30    536    2.04     0.45     0.15
  \[[@B45-ijms-16-00704]\]   2005   Spain/Caucasian           Population-based   PCR-SSCP            35      24         2     28    94     346    166   18   202   858    0.12     0.38     0.73
  \[[@B46-ijms-16-00704]\]   2006   Mexico/-                  Population-based   PCR-RFLP            262     123        11    145   647    582    261   30   321   1425   0.01     0.44     0.91
  \[[@B47-ijms-16-00704]\]   2006   German/Caucasian          Cohort             RT-PCR              299     60         6     72    658    263    53    7    67    579    4.45     0.15     0.03
  \[[@B48-ijms-16-00704]\]   2007   UK/Caucasian              Population-based   PCR-RFLP            116     25         7     39    257    1968   536   35   606   4472   0.05     ＜0.01   0.83
  \[[@B49-ijms-16-00704]\]   2008   Polish/Caucasian          Population-based   PCR-RFLP            117     10         2     14    244    108    8     1    10    224    3.16     ＜0.01   0.08
  \[[@B49-ijms-16-00704]\]   2009   Russian/Caucasian         Population-based   PCR--RFLP           427     67         1     69    921    368    66    1    68    802    1.21     0.33     0.27
  \[[@B49-ijms-16-00704]\]   2009   Iranian/Caucasian         Population-based   PCR-RFLP            31      17         4     25    79     42     10    0    10    94     0.59     0.5      0.44
  \[[@B49-ijms-16-00704]\]   2010   Brazilian/Asian           Population-based   PCR-DS              93      95         12    119   281    100    85    15   115   285    0.28     0.05     0.6
  \[[@B49-ijms-16-00704]\]   2010   Iranian/Caucasian         Population-based   PCR-RFLP            171     63         7     77    405    117    47    9    65    281    2.08     0.68     0.15
  \[[@B49-ijms-16-00704]\]   2012   Saudi Arabia/ Caucasian   Population-based   ARMS-PCR            220     72         6     84    512    209    80    9    98    498    0.16     0.96     0.69

PCR, polymerase chain reaction; DS, direct sequencing; RFLP, restriction fragment length polymorphisms; RT, Real-Time; SBE, single base extension; ARMS, amplification refractory mutation system; SSCP, single strand conformation polymorphism; and HWE, Hardy-Weinberg equilibrium.
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2.2. Pooled Analyses
--------------------

In the whole population, a significant association was found between the *ADIPOQ* gene +45T\>G polymorphism and the T2DM under allelic (OR: 1.18, 95% CI: 1.06--1.32, *p* = 0.002), dominant (OR: 1.18, 95% CI: 1.03--1.34, *p* = 0.014), recessive (OR: 1.47, 95% CI: 1.20--1.80, *p* \< 0.001), homozygous (OR: 1.62, 95% CI: 1.25--2.09, *p* \< 0.001), and heterozygous (OR: 1.11, 95% CI: 0.98--1.24, *p* = 0.11).

In the subgroup analysis, there was a significant association between them in the Asian population under allelic (OR: 1.27, 95% CI: 1.11--1.45, *p* \< 0.001), dominant (OR: 1.27, 95% CI: 1.07--1.51, *p* = 0.007), recessive (OR: 1.63, 95% CI: 1.30--2.06, *p* \< 0.001), homozygous (OR: 1.87, 95% CI: 1.38--2.54, *p* \< 0.001), and heterozygous (OR: 1.17, 95% CI: 1.00--1.38, *p* \< 0.001). However, in the Caucasian subgroup, there was no significant association between the *ADIPOQ* gene +45T\>G polymorphism and T2DM under allelic (OR: 0.95, 95% CI: 0.83--1.08, *p* = 0.212), dominant (OR: 0.92, 95% CI: 0.81--1.04, *p* = 0.443), recessive (OR: 1.05, 95% CI: 0.67--1.64, *p* = 0.150), homozygous (OR: 1.03, 95% CI: 0.66--1.62, *p* = 0.145), and heterozygous (OR: 0.92, 95% CI: 0.81--1.05, *p* = 0.647). ([Figure 2](#ijms-16-00704-f002){ref-type="fig"}A--E).

###### 

Forest plots for the *ADIPOQ* gene +45T\>G polymorphism and T2DM risk in different genetic models. (**A**) Allelic model: G *vs.* T; (**B**) Dominant model: GG + GT *vs.* TT; (**C**) Recessive model: GG *vs.* GT + TT; (**D**) Homozygous model: GG *vs.* TT; and (**E**) Heterozygous model: GT *vs.* TT.
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2.3. Sensitivity Analysis
-------------------------

We first performed a sensitivity analysis by sequence, excluding individual studies to reflect the influence of the individual data set to the pooled ORs. The results showed that none of the individual studies influenced the final conclusion. The corresponding pooled Ors were not altered substantially (data not shown), indicating that our meta-analysis had reliable and stable results.

2.4. Publication Bias Analysis
------------------------------

Begg's funnel plot and Egger's test were performed to determine whether the literature showed a publication bias. Begg's funnel plots did not exist in overall comparisons except the allelic model and the dominant model (shown in [Figure 3](#ijms-16-00704-f003){ref-type="fig"}A--E), the effect sizes were asymmetrically distributed with publication bias visually present. In addition, the results of Egger's regression test also showed evidence of publication bias (*p* = 0.023 for allele model, *p* = 0.016 for dominant model, *p* = 0.014 for recessive model, *p* = 0.019 for homozygous model, *p* = 0.094 for heterozygous model, respectively).

![Funnel plots for *ADIPOQ* gene +45T\>G polymorphism and T2DM risk in different genetic model. (**A**) Allelic model: G*vs.* T; (**B**) Dominant model: GG+GT*vs.* TT; (**C**) Recessive model: GG *vs.* GT+TT; (**D**) Homozygous model: GG*vs.* TT; and (**E**) Heterozygous model: GT*vs.* TT.](ijms-16-00704-g003){#ijms-16-00704-f003}

3. Discussion
=============

The *ADIPOQ* gene is located on human chromosome 3q27, where a region composed of three exons that span 17 kb, identified as a susceptibility locus for metabolic syndrome and T2DM, has been reported \[[@B55-ijms-16-00704],[@B56-ijms-16-00704],[@B57-ijms-16-00704]\]. T2DM is a complex heterogeneous group of metabolic disorders including hyperglycemia and impaired insulin action and/or insulin secretion, and a detailed etiology underlying T2DM is still unclear \[[@B58-ijms-16-00704],[@B59-ijms-16-00704]\]. Therefore, it is necessary to identify the pathogenesis of T2DM. Recently, the *ADIPOQ* gene +45T\>G polymorphism has been suggested to be implicated in the risk for type 2 diabetes, however, association studies have reported conflicting results. This may be due to a small sample size in each of the published studies and the ethnicity of these study populations. However, the results of these studies were still controversial. Therefore, we designed this meta-analysis to derive a more precise association between the *ADIPOQ* gene +45T\>G polymorphism and T2DM risk.

In the current meta-analysis, a significant association was detected in the whole population between the *ADIPOQ* gene +45T\>G polymorphism and T2DM under allelic, dominant, recessive and the homozygous genetic model, except the heterozygous model. Because the risk allele frequency of +45T\>G differed greatly among ethnicities, we performed subgroup analyses according to ethnicity. We obtained the following results: In Asians, the *ADIPOQ* gene +45T\>G polymorphism was significantly associated with risk of type 2 diabetes, while it was not found to be associated with risk of type 2 diabetes in Caucasians. In conclusion, it was indicated that the G allele of *ADIPOQ* gene +45T\>G polymorphism might be a predisposing factor to T2DM in the Asian population, whereas we did not find any association between T2DM and *ADIPOQ* +45T\>G in the Caucasian population. The discrepancy might be caused by differences in the *ADIPOQ* +45T\>G genotype distribution in different ethnic backgrounds \[[@B60-ijms-16-00704]\]. This result differs from that of Han *et al.* \[[@B61-ijms-16-00704]\], who showed that the presence of +45T\>G appeared to have no effect in Asians and whites. Menzaghi *et al.*, conducted a meta-analysis to explore the associations of different *ADIPOQ* SNPs with insulin resistance, T2DM and cardiovascular disease \[[@B62-ijms-16-00704]\]. However, Menzaghi and colleagues did not observe significant global effects between +45T\>G polymorphism considered in their meta-analysis. Li *et al.*, also observed no association between +45T\>G polymorphism and T2DM on the Han Chinese population \[[@B63-ijms-16-00704]\]. Their conclusions were not consistent with our study, and we found that the G *vs.* T allele of +45T\>G might be associated with T2DM risk. One possible explanation is that different populations may have experienced very diverse environmental impacts during their evolution. In addition, different life style as well as study sample size might also have contributed to this difference.

Significant between-study heterogeneity existed in all models, which may affect the results of the present meta-analysis. Common sources of heterogeneity may be attributed to the diversity in ethnicity, sample size, genotype errors, publication bias and different study design (population-based, hospital-based, or cohort) and diagnostic criteria *etc.* \[[@B63-ijms-16-00704],[@B64-ijms-16-00704],[@B65-ijms-16-00704]\]. We tried to clarify the sources of heterogeneity according to the subgroup analysis by ethnicity. However, we did not effectively remove the heterogeneity. We therefore assumed that all the potential sources mentioned above should be taken into account.

When explaining our results, some limitations of this meta-analysis should be considered. Several possible reasons may account for the difference between Asians and Caucasians in the association of the *ADIPOQ* gene +45T\>G polymorphism with type 2 diabetes. Firstly, different genetic background may play a role. T2DM is the result of diverse gene-environment interactions; we could not retrieve more detailed individual data, which were available, such as occupation, histological types and so on. In the Asian subgroup, the result showed a high level of between-study heterogeneity, suggesting that the studies do not estimate the same effect due to different degree of bias. In addition, there are significant differences regarding etiological profiles between high and low incidence areas within Asian. Secondly, our search was limited to published English and Chinese language studies, with studies published in other languages systematically excluded. This may explain some publication bias in our meta-analysis, which may have affected the results of this meta-analysis in as far as those studies that had produced negative results might not have been published. Thirdly, type 2 diabetes is a complex disease which is affected by an interplay between many factors, including environmental exposure, life style, socioeconomic status and individual susceptibility \[[@B66-ijms-16-00704],[@B67-ijms-16-00704]\]. It is possible that individual susceptibility in different ethnic groups may be modified by environmental exposure, life style and socioeconomic status in a different way. However, it is noted that although this meta-analysis has revealed a positive association between the *ADIPOQ* gene +45T\>G polymorphism and type 2 diabetes, the result needs to be interpreted in cautiously. The total sample size of Asians in this meta-analysis is still relatively small (T2DM, 6299; Controls, 5673), which may restrict the statistical power for achieving a definitive conclusion. Therefore, case-control studies in larger samples are needed to confirm this correlation.

Some studies have demonstrated that the main insulin-sensitizing action of adiponectin results from decrease in hepatic gluconeogenesis, increase in muscle glucose transport and enhancement of energy consumption and fatty acid oxidation in peripheral tissues with the aim of increasing ATP production \[[@B68-ijms-16-00704],[@B69-ijms-16-00704]\]. In addition, a few articles had reported that the potential role of adiponectin on insulin secretion, as well as on energy expenditure, through central action \[[@B70-ijms-16-00704],[@B71-ijms-16-00704],[@B72-ijms-16-00704]\]. Fasshauer reported that T2DM is characterized by low-grade inflammation and increased circulating concentrations of inflammatory cytokines, which in turn are putative negative regulatory factors of the adiponectin gene \[[@B73-ijms-16-00704]\]. Clinical and experimental animal studies also reported a decline in adiponectin levels seems to identify insulin resistance before the development of overt diabetes. Reduced adiponectin levels may play an important causal role in the development of insulin resistance and type 2 diabetes. In this sense, the progress of adiponectin analogues holds great promise for clinical use in the prevention and treatment of diabetes \[[@B74-ijms-16-00704]\]. However, many questions need to be addressed before adiponectin can be used as a potent therapeutic target.

4. Materials and Methods
========================

4.1. Literature Search Strategy
-------------------------------

Potential eligible studies were identified by systematically searching the Medline, Embase, Pubmed, ISI Web of Knowledge, Ovid, Science Citation Index Expanded Database, Wanfang Database and China National Knowledge Infrastructure up to November 2013. The following free-text word or subject headings (Medical Subject Headings (MeSH)) terms were used: "diabetes mellitus" or "type 2 diabetes" or "type 2 diabetes mellitus" or "T2DM", "adiponectin" or "adiponectin" or "APM1" or "ACDC" or "ADIPOQ", "polymorphism" or "single nucleotide" or "single nucleotide polymorphisms" or "variant" or "mutation" or "mutant" or "SNP". Two independent reviewers performed searches in duplicate. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. Only published studies with full-text articles were included in our meta-analysis.

4.2. Inclusion and Exclusion Criteria
-------------------------------------

We reviewed abstracts of all citations and retrieved studies. The following criteria were used to include published studies: (1) Published in English or in Chinese; (2) Case-control study or cohort study; (3) Supplied the available genotype frequencies in cases and controls; (4) Available data to estimate an odds ratio (OR) with 95% confidence interval (CI); and (5) Genotype distribution in controls were in Hardy-Weinberg equilibrium (HWE). Studies were excluded if one of the following existed: (1) No control group; (2) Studies that contained overlapping data; and (3) No report about the genotype frequency, or insufficient information for data extraction.

4.3. Data Extraction
--------------------

Two investigators (Yaofu Fan and Kun Wang) extracted information from all eligible publications independently according to the inclusion criteria listed earlier. Any disagreement was adjudicated by consensus and consulting a third author (Shuhang Xu). The following characteristics were collected from each study: first author, year of publication, country/region, diagnosis criteria for T2DM, genotyping methods, major variant allele frequency in cases and controls, and *p* values for Hardy--Weinberg equilibrium (HWE) in the T2DM and control groups were summarized.

4.4. Statistical Methods
------------------------

Odds ratios with 95% CIs were calculated to assess the associations between *ADIPOQ* +45T\>G polymorphism and T2DM risk. Association under four different types of Ors was estimated, including homozygote model (GG *vs.* TT), heterozygous model (GT *vs.* TT), dominant model (GG + TG *vs.* TT), recessive model (GG *vs.* TG + TT) and an allele contrast model (G *vs.* T) for *ADIPOQ* +45T\>G polymorphism, respectively. All meta-analysis were performed using Stata statistical software (STATA version SE-10.1; Stata Corporation, College Station, TX, USA). The HWE was checked by applying a Chi-square goodness-of-fit test. The heterogeneity among the studies was calculated by Chi-square-based *Q*-tests with significance set at *p* \< 0.05 \[[@B75-ijms-16-00704]\]. If the heterogeneity existed among the individual studies, the pooled OR was assessed using random-effect model (DerSimonian and Laird method) \[[@B76-ijms-16-00704]\]. Or else, the fixed-effect model was adopted (the Mantel--Haenszel method) \[[@B77-ijms-16-00704]\]. The *Z*-test was used to estimate the pooled OR and the significance level was set at *p* \< 0.05. The significance of the pooled OR was determined by the *Z*-test, in which *p* \< 0.05 was considered significant. A sensitivity analysis was performed to identify potential outliers. Funnel plots, Egger's test and Begg's test were used to evaluate publication bias.

5. Conclusions
==============

This meta-analysis suggests that the *ADIPOQ* gene +45T\>G polymorphism may be associated with susceptibility to T2DM in the Asian population. However, it is still necessary to conduct larger sample studies using standardized unbiased genotyping methods and to explore the association among different ethnicities in the future.

Chao Liu designed the study; Yaofu Fan and Kun Wang collected samples and clinic information; Yaofu Fan analyzed data and wrote the paper; Yaofu Fan, Shuhang Xu, Guofang Chen, Hongjie Di and Meng Cao supervised the analysis, and editing of the manuscript.

The authors declare no conflict of interest.

[^1]: These authors contributed equally to this work.
